Healthcare in 2022: what you need to know
With the Covid-19 pandemic sending shockwaves in the hospital sector, healthcare providers will continue looking for ways to slowly rebuild …
Post
-
-
Médunik and Biocodex sign exclusive agreement for Diacomit in Canada
Médunik Canada has entered an exclusive promotional services agreement with Biocodex for Diacomit, a medication approved in Canada as an …
-
Sensorion secures approval for HearConnex Phase I/II study in France
Sensorion has received authorisation from the French National Agency for Medicines and Health Products Safety (ANSM) for its clinical trial application …
-
HR HealthCare rolls out Liv catheter for female self-catheterisation
US-based HR HealthCare has launched the Liv Pre-lubricated Intermittent Catheter, a device developed to support women managing their bladder health …
-
Norroy receives China’s clearance for Phase III study of 177Lu-NYM032
Norroy Bioscience has received approval from the National Medical Products Administration (NMPA) to start a Phase III clinical trial in …
-
Novartis signs $3.2bn drug delivery deal with Alteogen
Novartis has signed an agreement with Alteogen that could be worth up to $3.22bn for the development and commercialisation of …
-
Healthcare in 2022: what you need to know
With the Covid-19 pandemic sending shockwaves in the hospital sector, healthcare providers will continue looking for ways to slowly rebuild …
-
FDA grants 510(k) clearance to Medibyt’s CPETWise solution
Israeli digital health company Medibyt has received 510(k) clearance from the US Food and Drug Administration (FDA) for its CPETWise …
-
First patient receives BHB810 in BigHat Biosciences’ Phase I study
BigHat Biosciences has dosed the patient in a Phase I clinical trial of BHB810, an antibody-drug conjugate targeting Cadherin-17 (CDH17), …
-
Takeda and Weave Bio collaborate on AI-driven automation in drug development
Takeda has entered a collaboration to introduce Weave Bio’s AI-native regulatory automation platform across 14 ongoing drug development programmes in …
-
Scan.com secures $220m to expand US medical imaging network
Scan.com has raised $220m in a combined equity and debt financing round as the company seeks to expand its medical …
-
Jazz reports Phase III trial interim results for Ziihera combination
Jazz Pharmaceuticals has reported results from the second interim analysis of the Phase III HERIZON-GEA-01 trial evaluating Ziihera (zanidatamab-hrii) plus …
-
Kazia closes oversubscribed offering to fund paxalisib’s clinical development
Kazia Therapeutics has closed an oversubscribed public offering that could provide the company with up to $120m in gross proceeds …
-
Vesalio’s NATURE trial of enVast achieves primary endpoint
Vesalio has reported that the NATURE randomised controlled trial of its enVast Coronary Clot Retriever met the primary endpoint. The device …
-
Teva Pharmaceuticals to acquire BioXcel assets for up to $125m
Teva Pharmaceuticals International has made a bid to acquire a range of neuroscience assets from BioXcel Therapeutics for a total …
-
Verrica completes enrolment in Phase III trial of Ycanth
Verrica Pharmaceuticals has completed patient enrolment in its first pivotal Phase III trial, COVE-2, which is part of a global …
-
Philips and Imricor introduce MR lab solution for cardiac interventions
Royal Philips and Imricor Medical Systems have introduced a new interventional magnetic resonance (iMR) lab solution for cardiac interventions. This solution …